Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.645 USD | -1.50% | -11.09% | +17.28% |
01:00pm | Atai Life Sciences N.V. Announces Board and Supervisory Board Changes | CI |
May. 22 | Clarify Pharma confirms name change to File Forge | AN |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.28% | 280M | - | ||
+60.34% | 62.59B | B- | ||
-3.05% | 41.18B | B | ||
+44.76% | 40.29B | A | ||
-8.29% | 27.9B | C | ||
+12.55% | 26.21B | B- | ||
-21.60% | 19.09B | B | ||
+5.70% | 13.08B | B+ | ||
+24.54% | 12.26B | B+ | ||
+27.52% | 12.05B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ATAI Stock
- Ratings Atai Life Sciences N.V.